ArticleMolecular therapy : the journal of the American Society of Gene Therapy2021
Neoadjuvant Gene-Mediated Cytotoxic Immunotherapy for Non-Small-Cell Lung Cancer: Safety and Immunologic Activity.
Registry-linked trialOpen access · hybridAbstract read
In one paragraph
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03131037 (Intratumoral Gene Mediated Cytotoxic Immunotherapy), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 20% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Intratumoral Gene Mediated Cytotoxic Immunotherapy (GMCI) For Resectable Non-Small Cell Lung Cancer
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Research landscape, thematic evolution, and translational insights of immune checkpoint inhibitor-induced colitis: a bibliometric analysis (2006-2025).Frontiers in immunology · 2026Pooled it
- Prolonged survival after systemic immune reactivation by aglatimagene besadenovec plus valacyclovir in immune checkpoint inhibitor-refractory non-small cell lung cancer.Journal for immunotherapy of cancer · 2026Trial
- Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial.The Lancet. Oncology · 2026Trial
- Endobronchial Intratumoral Immuno- and Gene Therapies in Lung Cancer: Mechanisms of Local Delivery, Systemic Immune Effects, and Global Feasibility.International journal of molecular sciences · 2026Review
- Neoadjuvant intratumoral immune stimulation using gene-mediated cytotoxic immunotherapy for resectable non-small cell lung cancer: 5-Year outcomes.JTCVS open · 2026Article
- Therapeutic mRNA vaccines for lung cancer: reshaping the tumor microenvironment to enhance anti-tumor immunity.Frontiers in immunology · 2026Review
- Suicide gene therapy targeting ewing sarcoma via an ewing-specific GGAA promoter.Scientific reports · 2025Article
- Targeted inactivation of EWSR1 : : FLI1 gene in Ewing sarcoma via CRISPR/Cas9 driven by an Ewing-specific GGAA promoter.Cancer gene therapy · 2025Article
- Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy.Cancer research communications · 2025Article
- Genetically predicted Caspase 8 levels mediates the causal association between CD4+ T cell and breast cancer.Frontiers in immunology · 2024Article
- E3 ligase TRIM28 promotes anti-PD-1 resistance in non-small cell lung cancer by enhancing the recruitment of myeloid-derived suppressor cells.Journal of experimental & clinical cancer research : CR · 2023Article
- Effectiveness of immunological agents in non-small cell lung cancer.Cancer reports (Hoboken, N.J.) · 2023Review
- Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models.Journal for immunotherapy of cancer · 2022Article
- Effector Mechanisms of CD8+ HLA-DR+ T Cells in Breast Cancer Patients Who Respond to Neoadjuvant Chemotherapy.Cancers · 2021Article
- Article
- [Questions and Answers in Lung Cancer].Open respiratory archivesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 2 institutions in 1 country.
Jarrod D PredinaAbramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Division of Thoracic Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Andrew R HaasAbramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Division of Pulmonary, Allergy and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Marina MartinezAbramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Division of Pulmonary, Allergy and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Shaun O'BrienDivision of Pulmonary, Allergy and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Edmund K MoonAbramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Division of Pulmonary, Allergy and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Patrick WoodruffAbramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Division of Pulmonary, Allergy and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Jason StadanlickAbramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Division of Thoracic Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Christopher CorbettAbramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Division of Thoracic Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Lydia Frenzel-SulyokAbramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Division of Thoracic Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Mitchell G BryskiAbramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Division of Thoracic Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Evgeniy EruslanovAbramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Division of Thoracic Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Charuhas DeshpandePulmonary and Mediastinal Pathology, Department of Clinical Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Corey LangerAbramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, MA, USA.
Laura K AguilarAdvantagene, Inc. d.b.a. Candel Therapeutics, Needham, MA, USA.
Brian W GuzikAdvantagene, Inc. d.b.a. Candel Therapeutics, Needham, MA, USA.
Andrea G ManzaneraAdvantagene, Inc. d.b.a. Candel Therapeutics, Needham, MA, USA.
Estuardo Aguilar-CordovaAdvantagene, Inc. d.b.a. Candel Therapeutics, Needham, MA, USA.
Sunil SinghalDivision of Thoracic Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Steven M AlbeldaAbramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Division of Pulmonary, Allergy and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: albelda@pennmedicine.upenn.edu.
University of Pennsylvania · USAdvantagene (United States) · US
Funding
TUMOR HYPOXIA, PHOTOSENSITIZER, VASCULARITY AND PDTP01CA087971 · NCI · UNIVERSITY OF PENNSYLVANIA · PI BUSCH, THERESA M, CENGEL, KEITH A · 2001 to 2019
$24.8MIMMUNOBIOLOGY OF NORMAL AND NEOPLASTIC LYMPHOCYTEST32CA009140 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Malay Haldar, WARREN S PEAR · 1985 to 2026
$16.1MNear infrared intraoperative molecular imaging of lung adenocarcinomaR01CA193556 · NCI · UNIVERSITY OF PENNSYLVANIA · PI LOW, PHILIP STEWART, SINGHAL, SUNIL · 2016 to 2020
$3.3MTumor-associated neutrophils in human lung cancerR01CA187392 · NCI · UNIVERSITY OF PENNSYLVANIA · PI ERUSLANOV, EVGENIY · 2016 to 2020
$1.8MUse of Genetically Engineered T cells Targeting Tumor Stroma to Treat Lung CancerR01CA172921 · NCI · UNIVERSITY OF PENNSYLVANIA · PI ALBELDA, STEVEN MARK · 2013 to 2017
$1.8MOptimizing Immunotherapy Strategies to Eliminate Recurrences after Cancer SurgeryF32CA210409 · NCI · UNIVERSITY OF PENNSYLVANIA · PI PREDINA, JARROD D · 2016 to 2017
$132kNCI NIH HHS F32 CA210409NCI NIH HHS P01 CA087971NCI NIH HHS R01 CA172921NCI NIH HHS R01 CA187392NCI NIH HHS R01 CA193556NCI NIH HHS T32 CA009140
Abstract
Gene-mediated cytotoxic immunotherapy (GMCI) is an immuno-oncology approach involving local delivery of a replication-deficient adenovirus expressing herpes simplex thymidine kinase (AdV-tk) followed by anti-herpetic prodrug activation that promotes immunogenic tumor cell death, antigen-presenting cell activation, and T cell stimulation. This phase I dose-escalation pilot trial assessed bronchoscopic delivery of AdV-tk in patients with suspected lung cancer who were candidates for surgery. A single intra-tumoral AdV-tk injection in three dose cohorts (maximum 10
Indexed as
Genetic TherapyAdenoviridaeCarcinoma, Non-Small-Cell LungCD8-Positive T-LymphocytesCytotoxicity, ImmunologicGenetic VectorsHumansImmunotherapyLung NeoplasmsNeoadjuvant TherapyThymidine KinaseThymidine Kinaseadenoviruscheckpoint inhibitorgene-mediated cytotoxic immunotherapygene therapyimmunotherapyintratumoral immunotherapylung cancerneoadjuvant clinical trialPD-1PD-L1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
NCT03131037ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.